RecruitingEarly Phase 1NCT06744816

Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study


Sponsor

M.D. Anderson Cancer Center

Enrollment

20 participants

Start Date

Dec 11, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

To learn if topical capsaicin can help relieve pain from CIPN and improve gait (the pattern of walking) in patients.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Participants diagnosed with pain of the lower extremity from chronic (>90 days duration) CIPN (due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds), seen at MD Anderson Cancer Center
  • Participants reporting baseline pain ≥ 4 (0-10 scale, NRS)
  • Participants age 18+
  • Participants who have completed chemotherapy within the last year at the time of enrollment.

Exclusion Criteria5

  • Participants with cognitive dysfunction
  • Participants with recent history (<6 months) of drug or alcohol abuse
  • Participants with open skin lesion or undergoing antibiotic therapy for local for systemic infection
  • Participants with allergies to capsaicin or adhesives
  • Pregnant participants

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGQutenza Patch

Given topical


Locations(1)

MD Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06744816


Related Trials